RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.61%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$870M
AUM Growth
+$870M
(-11%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-12.27%
Top 10 Holdings %
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10
Top Buys
| 1 |
Glaukos
GKOS
|
$23M |
| 2 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 3 |
Elevance Health
ELV
|
$11.2M |
| 4 |
Molina Healthcare
MOH
|
$11.2M |
| 5 |
DexCom
DXCM
|
$10.6M |
Top Sells
| 1 |
Merck
MRK
|
$21.9M |
| 2 |
Inspire Medical Systems
INSP
|
$21.4M |
| 3 |
Cigna
CI
|
$16.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14.7M |
| 5 |
Boston Scientific
BSX
|
$14.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $40.6M | 4.66% | 77,430 +16,900 | +28% | +$8.85M |
|
2
Eli Lilly
LLY
$657B
| $34.5M | 3.96% | 41,750 -3,700 | -8% | -$3.06M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $32.4M | 3.72% | 66,750 +16,750 | +34% | +$8.12M |
|
4
McKesson
MCK
$85.4B
| $31.8M | 3.65% | 47,217 +13,100 | +38% | +$8.82M |
|
|
5
Boston Scientific
BSX
$156B
| $30.3M | 3.48% | 300,000 -144,000 | -32% | -$14.5M |
|
|
6
Glaukos
GKOS
$5.5B
| $26.6M | 3.05% | 270,000 +233,469 | +639% | +$23M |
|
7
Gilead Sciences
GILD
$140B
| $26.2M | 3.01% | 233,500 -22,000 | -9% | -$2.47M |
|
8
Procept Biorobotics
PRCT
$2.23B
| $26.1M | 3% | 448,000 +27,655 | +7% | +$1.61M |
|
9
Intuitive Surgical
ISRG
$170B
| $25.5M | 2.93% | 51,500 -12,500 | -20% | -$6.19M |
|
10
Alignment Healthcare
ALHC
$3.24B
| $24.9M | 2.86% | 1,337,284 -423,908 | -24% | -$7.89M |
|
11
Medtronic
MDT
$119B
| $22.9M | 2.63% | 255,000 -14,500 | -5% | -$1.3M |
|
|
12
Molina Healthcare
MOH
$9.8B
| $22.5M | 2.58% | 68,200 +34,000 | +99% | +$11.2M |
|
|
13
Elevance Health
ELV
$71.8B
| $21.3M | 2.45% | 48,950 +25,800 | +111% | +$11.2M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $20.1M | 2.31% | 31,750 -11,707 | -27% | -$7.42M |
|
15
Cooper Companies
COO
$13.4B
| $19.9M | 2.29% | 236,000 +121,000 | +105% | +$10.2M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $19.8M | 2.28% | +325,000 | New | +$19.8M |
|
17
Natera
NTRA
$23.1B
| $19.6M | 2.25% | 138,500 +15,090 | +12% | +$2.13M |
|
18
Exact Sciences
EXAS
$8.98B
| $19M | 2.19% | 440,000 -31,000 | -7% | -$1.34M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $18.7M | 2.15% | 265,000 +14,377 | +6% | +$1.02M |
|
20
AbbVie
ABBV
$372B
| $18.6M | 2.13% | 88,650 -35,500 | -29% | -$7.44M |
|
21
Tenet Healthcare
THC
$16.3B
| $17M | 1.96% | 126,700 -71,000 | -36% | -$9.55M |
|
22
Insulet
PODD
$23.9B
| $16M | 1.84% | 61,000 +4,000 | +7% | +$1.05M |
|
23
CVS Health
CVS
$92.8B
| $16M | 1.84% | 235,862 -31,638 | -12% | -$2.14M |
|
24
Jazz Pharmaceuticals
JAZZ
$7.75B
| $15.4M | 1.77% | 124,300 -21,200 | -15% | -$2.63M |
|
25
Insmed
INSM
$28.8B
| $14.2M | 1.63% | 185,500 +124,000 | +202% | +$9.46M |
|